Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
The Ras Gene02:38

The Ras Gene

6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory <i>EGFR</i>-mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study.

Therapeutic advances in medical oncology·2026
Same author

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Nature communications·2026
Same author

GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy.

Nature communications·2026
Same author

Efficacy of immunotherapy in advanced <i>ALK</i>-rearranged non-small cell lung cancer patients with disease progression on ALK-TKIs.

Translational lung cancer research·2025
Same author

Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer.

Cell death & disease·2025
Same author

Therapeutic targeting de novo purine biosynthesis driven by β-catenin-dependent PPAT upregulation in hepatoblastoma.

Cell death & disease·2025

相关实验视频

Updated: Sep 9, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

在KRASG12C突变肺癌中,WEE1抑制剂通过MYBL2-RRM2轴与KRAS G12C抑制剂产生协同作用

Chao Zhou1, Yuqing Liu2, Hongyu Liu1

  • 1Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Cell death & disease
|August 30, 2025
PubMed
概括
此摘要是机器生成的。

将KRAS G12C抑制剂与WEE1激酶抑制剂结合使用对肺癌治疗具有前景. 这种组合针对MYBL2- RRM2轴,提高治疗效率超出单一治疗.

更多相关视频

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

相关实验视频

Last Updated: Sep 9, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

科学领域:

  • 癌症学
  • 分子生物学
  • 药物开发

背景情况:

  • 克拉斯G12C抑制剂 (G12Ci) 在单一治疗中具有有限的临床疗效.
  • 开发组合策略对于提高G12Ci的有效性至关重要.
  • MYBL2-RRM2轴与肺癌的预后不佳有关.

研究的目的:

  • 研究WEE1激酶抑制剂 (WEE1i) 与G12Ci结合用于肺癌治疗的潜力.
  • 阐明G12Ci和WEE1i联合治疗的协同效应的分子机制.
  • 在临床前肺癌模型中评估这种组合的治疗效果.

主要方法:

  • 使用基于细胞的测试来评估药物协同作用和分子标.
  • 研究了MYBL2-RRM2轴在药物反应中介作用.
  • 使用瘤异种移植模型来评估组合治疗的体内疗效.

主要成果:

  • 通过MYBL2-RRM2轴对KRAS G12C抑制剂 (G12Ci) 产生敏感性.
  • 过度表达MYBL2- RRM2或补充RRM2产品部分扭转了协同效应.
  • 在临床前的异种移植模型中,组合疗法表现出显著的抗瘤活性.

结论:

  • 像Adavosertib这样的WEE1激酶抑制剂可以增强KRAS G12C抑制剂的疗效.
  • MYBL2-RRM2轴是协同效应的关键媒介.
  • 临床上可用的WEE1抑制剂是改善G12Ci治疗肺癌的有希望的策略.